Louisiana State Employees Retirement System Purchases Shares of 9,300 IDEXX Laboratories, Inc. $IDXX

Posted by Stanley Muller on Jun 27th, 2026

Louisiana State Employees Retirement System acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) in the first quarter, HoldingsChannel.com reports. The firm acquired 9,300 shares of the company’s stock, valued at approximately $5,226,000.

Several other large investors also recently modified their holdings of the stock. Elyxium Wealth LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $3,666,459,000. J. Stern & Co. LLP lifted its position in IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock worth $1,795,072,000 after acquiring an additional 2,642,200 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after acquiring an additional 1,442,174 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of IDEXX Laboratories by 318.1% during the fourth quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after acquiring an additional 592,834 shares during the period. Finally, Norges Bank bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $332,265,000. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Down 0.6%

Shares of IDXX stock opened at $551.50 on Friday. The stock has a market cap of $43.50 billion, a P/E ratio of 40.61, a price-to-earnings-growth ratio of 3.04 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a 50 day simple moving average of $558.79 and a 200 day simple moving average of $614.78.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the company earned $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of recent research reports. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Weiss Ratings upgraded IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. UBS Group lowered their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Finally, Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

View Our Latest Stock Report on IDXX

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Louisiana State Employees Retirement System Purchases Shares of 9,300 IDEXX Laboratories, Inc. $IDXX

IDEXX Laboratories Trading Down 0.6%

Analyst Upgrades and Downgrades

About IDEXX Laboratories

Recommended Stories

You might be interested in: